24/7 Market News Snapshot 09 June, 2025 – PolyPid Ltd. Ordinary Shares (NASDAQ:PYPD)

June 9, 2025

DENVER, Colo., 09 June, 2025 (www.247marketnews.com) – (NASDAQ:PYPD) are discussed in this article.
PolyPid Ltd. (PYPD) has recently experienced a significant increase in market activity, now trading at $4.418, up 35.1% from its previous close of $3.270. This surge is accompanied by a notable trading volume of 8.99 million shares, reflective of heightened investor interest and sentiment. Analysts view this upward trend as indicative of potential breakout opportunities, suggesting that investors may want to explore PolyPid Ltd. further for future growth prospects.

Contributing to this favorable outlook are the promising results from the company’s pivotal Phase 3 trial of D-PLEX100, aimed at reducing surgical site infections (SSIs) in patients undergoing major abdominal colorectal surgeries. The SHIELD II trial demonstrated that D-PLEX100, when combined with standard care, resulted in a statistically significant 38% reduction in primary endpoint events, a finding marked by strong statistical significance (p<0.005). Additionally, the first secondary endpoint revealed a remarkable 58% reduction in deep and superficial SSI rates among those treated with D-PLEX100, underscoring its efficacy in improving post-surgical outcomes. Dikla Czaczkes Akselbrad, CEO of PolyPid, expressed optimism regarding the findings, emphasizing D-PLEX100's potential to transform healthcare practices and reduce costs associated with surgical complications. With a total addressable market exceeding 12 million surgeries annually in the U.S., PolyPid is poised for meaningful growth. The company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in early 2026, followed by a Marketing Authorization Application (MAA) in Europe. The robust data from the trial is expected to catalyze interest in global partnerships, and PolyPid is set to present further details at an upcoming medical conference to enhance awareness of this innovative therapeutic solution.

Related news for (PYPD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.